1Kuehl P, Zhang J, Lin Y, et al . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J ] .Nat Genet, 2001,27(4) : 383.
2Hu YF,He J ,Chen GL, et al. CYP3A5* 3 and CYP3A4 *18 single nucleotide polymorphisms in a Chinese population [J ] . Clin Chim Acta , 2005,353( 1- 2) : 187.
4Haufroid V, Mourad M, van Kerckhove V, et al . The effect of CYP3A5 and MDRI(ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels instable renal transplant patients [ J ] . Pharmacogenetics , 2004,14 ( 3 ): 147.
5Hesselink DA, van Schaik RH, van der Heiden IP,et al . Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR 1 genes and pharmacokinetics of the calcineur in inhibitors cyclosporine and tacrolimus[J ]. Clin Pharmacol Ther, 2003,74(3) : 245.
7Le Meur Y,Djebli N,Szelag JC,et al .CYP3A5* 3 influences sirolimus oral clearance in de novo and stable renal transplant recipients[J]. Clin Pharmacol Ther , 2006,80(1) : 51.
8Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid - lowering response to statins is affected by CYP3A5 polymorphism[J ]. Pharmacogenetics, 2004 , 14(8) : 523.
9Williams ML,Morris MT,Ahmad U,et al .Racial differences in compliance with NCEP - Ⅱ recommendations for secondary prevention at a Veterans Affairs medical center[J ] . Ethn Dis ,2002,12(Suppl 1) :58.
10Kim KA, Park PW, Lee OJ, et al .Effect of polymorphic CYP3A5 genotype on the single - dose simvastatin pharmacokinetics in healthy subjects[J] .J Clin Pharmacol, 2007,47(1) :87.
二级参考文献31
1Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in tran scriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics,2000,10(5) :415
2Lee SJ, Usmani K, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics, 2003,13: 461
3Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc Natl Acad Sci U S A, 1987,84:7735
4Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev, 1997,27(2-3) :201
5Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet,2001,40:159
6Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.Drugs, 1997,54:925
7Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms.Am J Transplant, 2003,3 (4): 477
8Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyelosporine and tacrolimus. Clin Pharmacol Ther,2003,74(3) :245
9Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation,2003,76(8) :1233
10Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.J Clin Pharmacol, 2004,44(2): 135
